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Abstract
Objective
Inflammation and anti-inflammatory treatments might influence the risk of diabetes. The
objective of this study was to assess factors associated with incident diabetes in rheumatoid
arthritis (RA).
Methods
The study population consisted of RA patients from a multi-center cohort study, Corrona. To
assess risk associated with disease modifying antirheumatic drug (DMARD) exposure, we
assessed five mutually exclusive DMARD groups. Additionally, we assessed the risk associ-
ated with body mass index (BMI, <25, 25–30, >30 kg/m2) and glucocorticoid usage. Incident
cases of diabetes were confirmed through adjudication, and Cox regression models were fit
to estimate the risk of incident diabetes.
Results
We identified 21,775 DMARD treatment regimens, the mean (SD) age at the index visit was
58 (13) years, disease duration 10 (10) years, and 30% used oral glucocorticoids at the
time. Eighty-four incident cases of diabetes were confirmed within the treatment exposure
periods. The hazard ratio (HR, 95% confidence interval) for diabetes was significantly
reduced in patients receiving TNF inhibitors, HR 0.35 (0.13, 0.91), compared to patients
treated with non-biologic DMARDs other than hydroxychloroquine and methotrexate.
Hydroxychloroquine, methotrexate and use of other biologic DMARDs had a numerically
reduced risk compared to the same group. Patients prescribed�7.5 mg of glucocorticoids
had a HR of 2.33 (1.68, 3.22) of incident diabetes compared with patients not prescribed
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Data Availability Statement: The Corrona dataset
is based on a large US multicenter study adhering
to a number of institutional review boards, with
complex logistics. Patients did not provide consent
to raw data sharing during the data collection for
this purpose, and the Corrona data sharing policies
do not permit raw data sharing for this purpose.
Corrona data are kept in multiple locations to
ensure multiple independent copies of the data. No
data are provided with this paper. However,
qualified investigators can contact Corrona,
represented by Heather Litman (hlitman@corrona.
oral glucocorticoids. RA patients with a BMI >30 had a HR of 6.27 (2.97, 13.25) compared to
patients with BMI�25.
Conclusion
DMARDs, glucocorticoids and obesity influenced the risk of incident diabetes in a large
cohort of RA patients. Monitoring for the occurrence of diabetes should be part of routine RA
management with a focus on specific subgroups.
Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory disease, characterized by joint pain, loss
of function and decreased quality of life [1]. During the last twenty years, the treatment for RA
has improved greatly, mainly due to the introduction of biologic disease modifying anti-rheu-
matic drugs (bDMARDs) and more aggressive treatment strategies, especially in early RA [1–
3]. RA patients increasingly receive treatment tailored to their disease activity, co-morbidities
and predictors of subsequent joint damage and loss of function.
Diabetes is a growing health problem worldwide. In 2015, 450 million people were esti-
mated to live with diabetes, of which more than 90% of cases are due to type 2 diabetes
[4]. Diabetes increases the risk of cardiovascular disease, blindness, kidney failure and
lower-limb amputation, and causes substantial morbidity and mortality in affected indi-
viduals [4]. RA is associated with abnormalities in the glucose metabolism, mainly insulin
resistance, a precursor to type 2 diabetes [5, 6], and data suggest an increased occurrence
of diabetes in RA patients, although studies are somewhat conflicting [7–9]. Tumor
necrosis factor (TNF)-alpha and IL-6 are involved in the pathogenesis of RA and insulin
resistance and diabetes [9]; systemic inflammation drives hyperglycemia [10, 11]. Block-
ade of interleukin-1 with the drug anakinra has been shown to improve glycemia and
beta-cell secretory function in patients with type 2 diabetes [12]. Obesity represents the
main risk factor for diabetes; it also correlates with higher RA disease activity, more dis-
ability and an increased risk of comorbidities in RA [13, 14].
The association between diabetes and RA raises important questions about whether
anti-inflammatory treatment in RA affects the likelihood of diabetes development. In a
study conducted in US administrative claims data, TNF inhibitors and hydroxychloro-
quine were associated with a reduced risk of diabetes when compared to other non-bio-
logic DMARDs (nbDMARDs) [15]. Other studies support that DMARDs, especially
hydroxychloroquine, might influence glucose tolerance and diabetes risk in RA [16–19].
Hydroxychloroquine has also shown a beneficial effect on glycosylated hemoglobin
(HbA1c) in diabetic RA patients [20]. Glucocorticoid use has been found to be associated
with diabetes in RA patients [21], although the reduction of inflammatory activity with
glucocorticoid treatment might modulate the relationship between glucocorticoids and
diabetes in RA patients [22].
Understanding factors associated with diabetes risk in RA should help guide the clini-
cian in treatment choices, especially in patients with other known risk factors for diabetes.
In this study, we assessed if choice of DMARDs and use of glucocorticoids is associated
with incident diabetes in RA after adjusting for other important risk factors for diabetes,
such as body mass index (BMI). We also study the relationship between obesity and diabe-
tes in RA.
Diabetes in rheumatoid arthritis
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Material and methods
Study design
The Consortium of Rheumatology Researchers of North America (Corrona) RA registry is a
US multicenter longitudinal observational study [23, 24]. More than 250 centers participate in
Corrona, including both academic and non-academic study sites. Corrona participants are
assessed at routine clinical encounters, and the data collection includes reports of comorbidi-
ties by the patient and physician, clinical assessment, drug utilization recorded at each visit,
patient reported outcome measures, and disease activity measures. The study was performed
in compliance with the Declaration of Helsinki, and all participants provided a written
informed consent. Approvals for practice-level data collection and analyses in Corrona are
obtained from local institutional review boards of participating academic sites and central
institutional review boards (Western and New England Institutional Review Boards) for pri-
vate practice sites.
Exposure variables
The index date for each treatment regimen was the first study visit where the physician reported
prescribing the DMARD. The exception was ongoing DMARD use at enrollment into Corrona,
which was included in the exposure assessment. DMARD exposure was classified in five mutually
exclusive groups predefined in the study protocol (Table 1). 1) TNF inhibitors, including combina-
tions with any nbDMARD; 2) other biologic DMARDs (bDMARDs), including combinations
with any nbDMARD; 3) methotrexate, including combinations with nbDMARDs except hydroxy-
chloroquine; 4) hydroxychloroquine, including combinations with nbDMARDs except methotrex-
ate; and 5) other nbDMARDs not used in combination with methotrexate, hydroxychloroquine or
bDMARDs (leflunomide, cyclosporine, sulfasalazine, azathioprine, minocycline, auranofin, peni-
cillamine). The last group, other nbDMARDs, was chosen as the reference group for the analyses.
Treatment regimens with either a combination of biologics or a combination including both meth-
otrexate and hydroxychloroquine were excluded from the analyses. Each subject could not contrib-
ute more than four treatment regimens, and treatment regimens were excluded if the patient had a
diagnosis of diabetes at the index date of the treatment regimen according to case report forms, or
if no follow-up information was available.
In the analysis of the relationship between glucocorticoid use and diabetes development,
glucocorticoid exposure was categorized according to the daily dosage of oral glucocorticoids
reported at the index date: none, 1–2.5 mg, 3–7 mg or 7.5 mg or more. BMI was calculated
based on height and weight (weight in kilograms / (height in meters x height in meters)).
Table 1. The classification of DMARD regimens applied in the analyses.
Exposure Groups Inclusion criteria for exposure group Exclusion criteria for exposure group
TNF inhibitors Use of etanercept, infliximab, adalimumab, certolizumab, golimumab Combination with any bDMARDs
Other bDMARDs Use of abatacept, rituximab, anakinra, tocilizumab Combination with any bDMARDs
Methotrexate Use of methotrexate Combination with any bDMARD or
hydroxychloroquine
Hydroxychloroquine Use of hydroxychloroquine Combination with any bDMARD or methotrexate
Other nbDMARDs Use of leflunomide, cyclosporine, sulfasalazine, azathioprine, minocycline, auranofin,
penicillamine
Use of any bDMARD, methotrexate or
hydroxychloroquine
Abbreviations: bDMARD: biologic diseasease modifying anti-rheumatic drug, DMARD: Disease-modifying anti-rheumatic drug, nbDMARDs: non-biologic disease
modifying anti-rheumatic drugs, TNF: tumor necrosis factor.
https://doi.org/10.1371/journal.pone.0210459.t001
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Study population
The selection of the study population is outlined in Fig 1. The Corrona dataset included 35448
subjects. We excluded patients with other non-RA forms of arthritis (n = 5687), patients who
did not receive DMARDs (n = 518), and patients with only one Corrona visit (n = 6183) or
concurrent juvenile idiopathic arthritis (n = 117), which left us with 22943 RA subjects with
potential treatment regimens of interest (Fig 1). In these patients, we included treatment regi-
mens with the defined DMARD exposure groups and any follow-up time in patients who did
not have a diagnosis of diabetes, which left us with 21,775 treatment regimens of interest.
Outcome
Incident diabetes represents the main study outcome. The presence of diabetes was registered on
the physician questionnaire at each visit, and adjudication was undertaken for all reported inci-
dent cases. Adjudication was based on a combination of chart reviews and patient interviews by
the individual investigation sites to confirm that the registered diabetes cases were in fact newly
diagnosed, and included reported onset of anti-diabetic medication and glycated hemoglobin
(HbA1C) if available. Patient-reported diagnosis of diabetes in the case report form was not suffi-
cient to be classified as an incident diabetes case. The case ascertainment questionnaire also asked
investigators to confirm the date of diabetes diagnosis. If the dates of diagnosis reported at the
Corrona visit and the chart review did not match, the date reported in the chart review was chosen
for the analyses. Cases occurred between July 30th 2002 and July 1st 2011.
Statistical methods
Mean values with standard deviation (SD) and percentages were used to describe characteris-
tics at the index visit of the treatment regimen as appropriate. Person-time, incidence rates
Fig 1. Flow-diagram. Illustration of the selection of treatment regimens for the analyses.
https://doi.org/10.1371/journal.pone.0210459.g001
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(cases per 1,000 person-years) with 95% confidence intervals (CIs) and incidence rate ratios
with 95% CIs were calculated for each treatment category, with other nbDMARDs as the refer-
ence category for the ratios.
Pair-wise propensity scores were calculated for each DMARD group with other
nbDMARDs as the comparator. Propensity score models included Clinical Disease Activity
Index (CDAI) [25] pain assessed on an visual analogue scale (VAS), RA disease duration, age,
BMI, gender, white vs. non-white race, insurance status, exercise status, subcutaneous nodules,
glucocorticoids (dichotomized, no glucocorticoids prescribed vs. glucocorticoids prescribed),
physical function assessed by the Modified Health Assessment Questionnaire (MHAQ [26]),
history of bDMARD use and history of nbDMARD use. A broad range of variables was
included in the propensity model to create a robust model with regards to individual con-
founding. In sensitivity analyses, history of bDMARD use was left out of the model.
To adjust for differences between DMARD treatment groups, we assessed Cox regression
models with adjustment for 1) age and gender 2) age, gender and BMI at onset of treatment
and 3) continuous propensity scores from the models described previously. In sensitivity anal-
yses, models adjusted for quintiles of propensity scores and continuous propensity score with
additional direct adjustment for BMI were assessed.
The associations of glucocorticoids and BMI to diabetes were assessed in separate Cox
regression models. Overweight was defined as a BMI of 25–30 kg/m2, obesity was defined as a
BMI of>30 kg/m2. Models were adjusted for the covariates thought to be the most relevant
risk factors of diabetes in this setting, namely age, family history of diabetes and DMARD
treatment.
Variables with missing values at the index date of the treatment regimen and likely stable
throughout the disease course were replaced with information from other visits if available,
including gender, race, smoking status, insurance and exercise. Time-varying variables and
stable variables still missing after replacement from other visits were imputed by multiple
imputation.
Confidence intervals for incidence rates and incidence rate ratios were calculated in
Episheet (www.drugepi.org). IBM SPSS Statistics version 20 was used for all other statistical
calculations.
Results
Patient characteristics
The mean (SD) age at the index visit was 58.2 (13.4) years and the mean disease duration 10.0
(9.8) years (Table 2). The mean score for the disease activity index CDAI was 13.4 (12.4), cor-
responding to moderate disease activity. Seventy-six percent of the population was women,
and 30% had a prescription of oral glucocorticoids at the index visit (Table 2).
Incident diabetes
We identified 82 incident cases of diabetes classified to have occurred within the follow-up
time defined for the treatment regimens included in the analyses. The diabetes incidence ran-
ged from 1.29 (95% CI 0.43, 3.07) cases per 1,000 person-years in patients receiving hydroxy-
chloroquine to 3.07 (95% CI 1.37, 6.03) cases per 1,000 person-years in patients receiving
other nbDMARDs. With other nbDMARDs as the reference, the incidence rate of diabetes
was lowest for patients using hydroxychloroquine (incidence rate ratio 0.42 [95% CI 0.12,
1.44]) and TNF inhibitors (incidence rate ratio 0.47 [95% CI 0.21, 1.07]), but these ratios
included the null.
Diabetes in rheumatoid arthritis
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Association between DMARDs and diabetes in multivariate models
In multivariate Cox regression models adjusting for continuous propensity scores, exposure to
TNF inhibitors was associated with reduced incidence of diabetes, with a hazard ratio of 0.35
(95% CI 0.13, 0.91, p-value 0.03, Table 3). Reduced hazard ratios were observed for the other
DMARD categories, but these findings were not statistically significant (Table 3). In sensitivity
analyses, similar results were found in Cox regression models adjusted for 1) propensity score
quintiles, 2) propensity scores and BMI, 3) propensity scores without history of bDMARD use
and 4) bDMARD use and propensity scores without history of bDMARD use.
Influence of glucocorticoids and BMI on the risk of diabetes
The risk of diabetes development increased with increasing doses of glucocorticoids. Patients
using�7.5 mg of glucocorticoids (n = 2045, 9.4%) had a HR of 2.33 (95% CI 1.68, 3.22) of
Table 2. Characteristics at start of treatment regimens for all patients, and each DMARD category separately for Corrona cohort.
Variables All treatment regimens
n = 21 775
TNF inhibitors
n = 9880
Other bDMARDs
n = 1756
Methotrexate
n = 7441
Hydroxychloroquine
n = 1496
Other nbDMARD
n = 1202
Age, mean (SD) 58.2 (13.4) 56.3 (13.2) 57.8 (13.1) 60.5 (13.3) 58.3 (13.7) 60.4 (13.1)
Disease duration, mean
(SD)
10.0 (9.8) 10.6 (9.6) 12.4 (9.6) 8.9 (10.0) 8.2 (9.2) 10.9 (10.1)
CDAI, mean (SD) 13.4 (12.4) 13.5 (12.5) 18.2 (13.9) 13.0 (12.2) 9.9 (10.1) 12.5 (11.9)
BMI, mean (SD) 28.7 (6.8) 28.7 (6.8) 29.1 (7.3) 28.7 (6.7) 28.4 (6.8) 28.4 (6.5)
28 swollen joint count,
mean (SD)
4.3 (5.5) 4.2 (5.5) 5.4 (5.8) 4.5 (5.8) 2.7 (3.9) 4.1 (5.5)
28 tender joint count,
mean (SD)
3.9 (5.7) 4.0 (5.8) 5.7 (6.7) 3.6 (5.4) 2.8 (4.7) 3.4 (5.3)
MHAQ, mean (SD) 0.36 (0.45) 0.36 (0.44) 0.53 (0.50) 0.33 (0.44) 0.30 (0.41) 0.34 (0.47)
Women, n (%) 16643 (76.4) 7670 (77.6) 1426 (81.2) 5458 (73.4) 1219 (81.5) 870 (72.4)
Smokers, n (%) 3516 (16) 1638 (17) 260 (14.9) 1197 (16.1) 220 (14.7) 189 (15.7)
Peroral glucocorticoid
use, n (%)
6538 (30) 2706 (27.4) 712 (40.5) 2331 (31.3) 404 (27.0) 385 (32.0)
Insurance, n (%) None 340 (1.6) 128 (1.3) 21 (1.2) 167 (2.2) 16 (1.1) 8 (0.7)
Only medicaid 494 (2.3) 212 (2.1) 35 (2.0) 179 (2.4) 34 (2.3) 34 (2.8)
Only medicare 3255 (14.9) 1231 (12.5) 303 (17.3) 1300 (17.5) 217 (14.5) 204 (17.0)
Private insurance 13901 (63.8) 6538 (66.2) 1311 (74.7) 4399 (59.1) 955 (63.8) 698 (58.1)
Medicare and medicaid 500 (2.3) 231 (2.3) 45 (2.6) 168 (2.3) 34 (2.3) 22 (1.8)
Missing 3285 (15.1) 1540 (15.6) 41 (2.3) 1228 (16.5) 240 (16.0) 236 (19.6)
Abbreviation: BMI: Body mass index, CDAI: clinical disease activity index, n: number of patients, SD: standard deviation, DMARD: disease modifying anti-rheumatic
drug.
https://doi.org/10.1371/journal.pone.0210459.t002
Table 3. Cox regression models assessing the relationship between DMARD exposure and diabetes.
Unadjusted models Adjusted for age and gender Adjusted for age, gender and
BMI
Propensity score adjusted
model�
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
TNF inhibitors vs other nbDMARDs 0.47 0.21, 1.06 0.07 0.50 0.22, 0.13 0.09 0.49 0.21, 1.11 0.09 0.35 0.13, 0.91 0.03
Other bDMARDs vs other nbDMARDs 0.49 0.14, 1.70 0.26 0.49 0.14, 1.78 0.27 0.50 0.14, 1.80 0.29 0.44 0.08, 2.57 0.36
Methotrexate vs other nbDMARDs 0.67 0.30, 1.52 0.34 0.68 0.30, 1.53 0.35 0.64 0.28, 1.46 0.29 0.67 0.44, 1.02 0.34
Hydroxychloroquine vs other nbDMARDs 0.42 0.12, 1.42 0.16 0.42 0.12, 1.46 0.17 0.42 0.12, 1.47 0.18 0.45 0.13, 1.53 0.21
� Propensity score models included CDAI, pain VAS, disease duration, age, BMI, gender, white vs. non-white, insurance, exercise, subcutaneous nodules,
glucocorticoids, MHAQ, history of bDMARD use, history of nbDMARD use.
https://doi.org/10.1371/journal.pone.0210459.t003
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incident diabetes compared with patients who were not prescribed oral glucocorticoids in
multivariate models (n = 14338, 65.8%, Table 4). In a sensitivity analysis with additional
adjustment for CDAI, glucocorticoids dosage was still associated with diabetes development.
No statistically significant increase in risk of diabetes was found for overweight RA patients,
although the point estimate of the model (HR 1.91, 95% CI 0.82 4.42) trended towards an
increased risk. Obese RA patients, defined by a BMI value >30 kg/m2, had a steep increase in
diabetes risk (HR 6.27, 95% CI 2.97, 13.25, Table 4). If assessing the effect of glucocorticoid
dose of�7.5 mg in patients with a BMI>30 kg/m2, the diabetes risk (HR 2.6, p-value 0.01,
95% CI 1.27 5.47)) was comparable to what was observed for the overall group of patients on
glucocorticoid doses of�7.5 mg.
Discussion
In this study, a significantly reduced risk of diabetes was found in RA patients treated with
TNF inhibitors when adjusting for covariates such as disease activity and BMI. In addition, the
risk of diabetes increased with increasing doses of glucocorticoids. The results might have clin-
ical implications when choosing RA treatment in patients with an increased risk of diabetes.
RA patients have a known increased risk of cardiovascular disease, which add to both mor-
bidity and mortality in these patients [8, 27, 28]. The combined effects of RA and diabetes on
cardiovascular risk are not well understood, but an interaction between these two risk factors
is likely. It is thus of special interest to prevent diabetes development in these patients. The
lower hazard ratio for diabetes observed in patients receiving TNF inhibitors in our study
underline that choice of RA treatment can have broad implications for the patient. However,
the effects observed may be a result of modulation of disease activity by bDMARDs and not a
direct effect of TNF inhibitor treatment. The trends observed for the other DMARD categories
did not reach statistical significance, although this might have been due to lack of statistical
power and should be interpreted within that context.
Treatment regimens with a combination of DMARDs and glucocorticoids have been
shown to effectively inhibit joint damage in RA, and glucocorticoids are commonly used in
RA treatment [2, 3, 29]. Contrary to the protective effect of TNF inhibitors, glucocorticoid use
was associated with a significant increase in risk of diabetes in our data, especially in patients
prescribed doses of 7.5 mg daily or more. Additionally, obese patients had a steep increase in
risk of diabetes compared to RA patients with a BMI�25 (HR 6.27, 95% CI 2.97, 13.25). This
risk is much higher than what has previously been reported in a Swedish study [13], and sup-
ports the importance of physical activity and dietary advice in this population. The higher rate
Table 4. Cox regression models assessing the relationship between prescription of glucocorticoids at index visit
and incident diabetes (top rows) and BMI at index date and incident diabetes (bottom rows), adjusted for
DMARD use, age and family history of diabetes.
Hazard ratio 95% CI P-value
Glucocorticoid prescription at index visit
0 mg Reference
1–2.5 mg 1.35 0.89, 2.03 0.6
3–7 mg 1.95 1.47, 2.58 <0.01
� 7.5 mg 2.33 1.68, 3.22 0.02
BMI
< 25 Reference
25–30 1.91 0.82, 4.42 0.13
> 30 6.27 2.97, 13.25 <0.01
https://doi.org/10.1371/journal.pone.0210459.t004
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might be due to differences in the obese populations (e.g. obese patients in the US having
higher BMI and participating in less physical activity than obese patients in Sweden), in pre-
scription patterns for glucocorticoids, or other unknown factors. Glucocorticoids are com-
monly prescribed for obese RA patients with insufficient control of disease activity. Further
studies are needed to investigate potential interactions between the observed risks of diabetes
development associated with obesity and glucocorticoids, the effects of cumulative glucocorti-
coid dosages, and whether alternative approaches such as intra-articular glucocorticoid injec-
tions should be preferred in these patients.
The study has certain limitations. Each reported case of incident diabetes was confirmed by
a combination of chart reviews and patient interviews by the individual investigation sites, but
HbA1c information was not collected. The case confirmation process might be the reason we
observed a rather low incidence rate of diabetes compared to previous reports from high risk
patients [30], however we have little reason to believe that this should be skewed between expo-
sure groups. A delayed diagnosis of diabetes might potentially lead to a case being attributed to
the wrong treatment episode. The treatment categories and choice of comparator group was
predefined to allow for comparison with previous results. We chose to not make post-hoc
adjustments although the data showed the comparator group, other non-biologic DMARDs,
to be relatively small. An alternative comparator group would have been methotrexate treat-
ment, but previous results indicating methotrexate to influence serum glucose levels [31] sup-
port a potential effect of methotrexate on diabetes development, making it less suitable as
comparator in these analyses. For some of the analyses a dataset of only patients who were
DMARD-naïve at inclusion would have been ideal, however this would be difficult to obtain
due to the number of observations necessary, and would limit the opportunity to study bio-
logic DMARDs. A comparator group of healthy individuals would have been of interest, but
were not available in this cohort. The inclusion of known risk factors for diabetes, e.g., disease
activity, family history and BMI, in the Corrona data collection is an advantage of the current
study, allowing us to better control for confounding by indication in analyses of DMARD and
glucocorticoid exposure. Additional strengths include the large number of observed treatment
regimens, and the diversity of the rheumatology centers participating in Corrona. Although it
is difficult to fully adjust for differences between the treatment groups in an observational
study, the results of the study are strengthened by the comparability to results found in previ-
ous studies RA and diabetes are two chronic conditions linked through a multitude of factors,
including the effects of anti-inflammatory treatment used to abate disease activity in RA. The
current study supports that potent treatment of RA with bDMARDs correlate with a reduced
risk of diabetes, thus reducing the burden of disease and risk of cardiovascular disease in these
patients. Contrary, an increased risk of diabetes was found in patients prescribed glucocorti-
coid doses of 3 mg daily or more. RA treatment in patients with a known increased risk of dia-
betes, such as BMI over 30 kg/m2, should be monitored with this in mind.
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